Cheng Y, Mok TS, Zhou X, et al. - In Asian patients included in the ongoing ARCHER 1050 trial (a randomized, open-label, phase 3 trial), researchers compared dacomitinib with gefitinib with respect to efficacy and safety when administered as first-line treatment for EGFR mutation-positive advanced NSCLC. Randomization (1:1) of 346 eligible patients with newly diagnosed advanced EGFR mutation-positive NSCLC was done to oral dacomitinib 45 mg/day or oral gefitinib 250 mg/day. PFS by blinded independent review was the primary endpoint. Findings revealed that a significantly longer PFS and improved OS was conferred by first-line dacomitinib vs gefitinib in this patient population. The adverse event profiles of both agents in Asian patients were identified to be consistent with the overall ARCHER 1050 population.